1. Home
  2. SLN vs PAYS Comparison

SLN vs PAYS Comparison

Compare SLN & PAYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.57

Market Cap

318.4M

Sector

Health Care

ML Signal

HOLD

Logo Paysign Inc.

PAYS

Paysign Inc.

HOLD

Current Price

$5.36

Market Cap

293.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
PAYS
Founded
1994
2001
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
318.4M
293.4M
IPO Year
N/A
1998

Fundamental Metrics

Financial Performance
Metric
SLN
PAYS
Price
$6.57
$5.36
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$39.67
$8.06
AVG Volume (30 Days)
314.1K
372.6K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.13
Revenue
$25,830,000.00
$74,879,428.00
Revenue This Year
N/A
$41.20
Revenue Next Year
N/A
$20.62
P/E Ratio
N/A
$42.18
Revenue Growth
40.39
32.61
52 Week Low
$1.97
$1.80
52 Week High
$8.08
$8.88

Technical Indicators

Market Signals
Indicator
SLN
PAYS
Relative Strength Index (RSI) 50.57 52.34
Support Level $5.95 $5.11
Resistance Level $6.60 $5.60
Average True Range (ATR) 0.53 0.19
MACD -0.03 0.05
Stochastic Oscillator 41.33 60.00

Price Performance

Historical Comparison
SLN
PAYS

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About PAYS Paysign Inc.

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.

Share on Social Networks: